⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for small lymphocytic lymphoma (sll)

Every month we try and update this database with for small lymphocytic lymphoma (sll) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological MalignanciesNCT03263637
Relapsed or Ref...
Acute Myeloid L...
Acute Lymphocyt...
Chronic Lymphoc...
High Risk Myelo...
Chronic Myelomo...
Richter's Syndr...
B-cell Non-Hodg...
T-cell Non-Hodg...
Small Lymphocyt...
Multiple Myelom...
AZD4573
18 Years - 130 YearsAstraZeneca
Study of XL114 in Subjects With Non-Hodgkin's LymphomaNCT05144347
Non-Hodgkin's L...
Activated B-Cel...
Mantle Cell Lym...
Chronic Lymphoc...
Small Lymphocyt...
XL114
18 Years - Exelixis
Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade LymphomaNCT01306643
Indolent Non-Ho...
Follicular Lymp...
Small Lymphocyt...
Marginal Zone L...
Idelalisib
18 Years - Gilead Sciences
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell MalignanciesNCT05753501
Hematologic Can...
ABBV-101
18 Years - AbbVie
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)NCT05105841
Chronic Lymphoc...
Small Lymphocyt...
Venetoclax
Ibrutinib
Obinutuzumab
20 Years - AbbVie
Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin LymphomasNCT01282424
Follicular Lymp...
Small Lymphocyt...
Lymphoplasmacyt...
Marginal Zone L...
Idelalisib
18 Years - Gilead Sciences
Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic MalignanciesNCT03588598
Chronic Lymphoc...
Small Lymphocyt...
B-Cell Non-Hodg...
SHC014748M
18 Years - 75 YearsNanjing Sanhome Pharmaceutical, Co., Ltd.
Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With VenetoclaxNCT04419519
Chronic Lymphoc...
Small Lymphocyt...
Venetoclax mono...
Venetoclax with...
18 Years - Memorial Sloan Kettering Cancer Center
Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic DiseasesNCT02145039
Acute Leukemias
Burkitt's Lymph...
Chronic Myeloge...
Fludarabine
Cyclophosphamid...
Total Body Irra...
Haploidentical ...
- 74 YearsMasonic Cancer Center, University of Minnesota
Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomaNCT01647971
Non-Hodgkins Ly...
B-cell Lymphoma
Waldenstrom's M...
Marginal Zone L...
Chronic Lymphoc...
Small Lymphocyt...
Primary Central...
Ublituximab
18 Years - TG Therapeutics, Inc.
A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination TherapyNCT03406156
Chronic Lymphoc...
Small Lymphocyt...
Obinutuzumab
Bendamustine
Venetoclax
18 Years - 99 YearsAbbVie
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell MalignanciesNCT05753501
Hematologic Can...
ABBV-101
18 Years - AbbVie
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell MalignanciesNCT05131022
Chronic Lymphoc...
Small Lymphocyt...
Diffuse Large B...
Follicular Lymp...
Mantle Cell Lym...
Marginal Zone L...
Waldenstrom Mac...
Primary Central...
NX-5948
18 Years - Nurix Therapeutics, Inc.
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AMLNCT03547115
Follicular Lymp...
Mantle Cell Lym...
Marginal Zone L...
Small Lymphocyt...
Chronic Lymphoc...
Diffuse Large B...
Acute Myeloid L...
voruciclib mono...
voruciclib and ...
18 Years - MEI Pharma, Inc.
A Study of MS-553 in Patients With Relapsed or Refractory B-cell LymphomaNCT05720052
Relapsed or Ref...
Diffuse Large B...
Follicular Lymp...
Mantle Cell Lym...
Chronic Lymphoc...
Small Lymphocyt...
Marginal Zone L...
MS-553
18 Years - MingSight Pharmaceuticals, Inc
Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)NCT01754870
Chronic Lymphoc...
Small Lymphocyt...
Bendamustine an...
18 Years - University of Wisconsin, Madison
Zanubrutinib and Venetoclax in CLL (ZANU-VEN)NCT05168930
Chronic Lymphoc...
Small Lymphocyt...
Venetoclax
Zanubrutinib
18 Years - Dana-Farber Cancer Institute
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)NCT00923507
Waldenstrom Mac...
Lymphoplasmacyt...
Monoclonal B-Ce...
Small Lymphocyt...
CLL (Chronic Ly...
18 Years - 110 YearsNational Institutes of Health Clinical Center (CC)
Zanubrutinib and Venetoclax in CLL (ZANU-VEN)NCT05168930
Chronic Lymphoc...
Small Lymphocyt...
Venetoclax
Zanubrutinib
18 Years - Dana-Farber Cancer Institute
A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid MalignanciesNCT00861510
Lymphoma, Mantl...
Leukemia, Lymph...
Leukemia, Hairy...
Waldenstrom Mac...
Multiple Myelom...
ON01910 Na
18 Years - 99 YearsNational Institutes of Health Clinical Center (CC)
Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic DiseasesNCT02145039
Acute Leukemias
Burkitt's Lymph...
Chronic Myeloge...
Fludarabine
Cyclophosphamid...
Total Body Irra...
Haploidentical ...
- 74 YearsMasonic Cancer Center, University of Minnesota
Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaNCT00694590
Chronic Lymphoc...
Small Lymphocyt...
plerixafor
18 Years - 80 YearsSanofi
First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell LymphomaNCT03625037
DLBCL
High-grade B-ce...
Primary Mediast...
FL
MCL
Small Lymphocyt...
Marginal Zone L...
Epcoritamab
18 Years - Genmab
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)NCT05105841
Chronic Lymphoc...
Small Lymphocyt...
Venetoclax
Ibrutinib
Obinutuzumab
20 Years - AbbVie
Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)NCT01497496
Chronic Lymphoc...
Small Lymphocyt...
High Dose Methy...
Ofatumumab
Lenalidomide
18 Years - H. Lee Moffitt Cancer Center and Research Institute
Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade LymphomaNCT01306643
Indolent Non-Ho...
Follicular Lymp...
Small Lymphocyt...
Marginal Zone L...
Idelalisib
18 Years - Gilead Sciences
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic MalignanciesNCT02362035
Follicular Lymp...
CLL
Small Lymphocyt...
Richter's Syndr...
Mantle Cell Lym...
Indolent Non Ho...
Waldenström Mac...
Multiple Myelom...
Hodgkin Lymphom...
Burkitt Lymphom...
Marginal Zone L...
Mediastinal Lar...
Hairy Cell Leuk...
Acalabrutinib
Pembrolizumab
18 Years - Acerta Pharma BV
Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaNCT00694590
Chronic Lymphoc...
Small Lymphocyt...
plerixafor
18 Years - 80 YearsSanofi
A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaNCT02966756
Chronic Lymphoc...
Small Lymphocyt...
Venetoclax
18 Years - AbbVie
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic MalignanciesNCT02362035
Follicular Lymp...
CLL
Small Lymphocyt...
Richter's Syndr...
Mantle Cell Lym...
Indolent Non Ho...
Waldenström Mac...
Multiple Myelom...
Hodgkin Lymphom...
Burkitt Lymphom...
Marginal Zone L...
Mediastinal Lar...
Hairy Cell Leuk...
Acalabrutinib
Pembrolizumab
18 Years - Acerta Pharma BV
A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLLNCT01203930
Chronic Lymphoc...
Small Lymphocyt...
Idelalisib
Rituximab
65 Years - Gilead Sciences
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell MalignanciesNCT04830137
Chronic Lymphoc...
Small Lymphocyt...
Waldenstrom Mac...
Mantle Cell Lym...
Marginal Zone L...
Follicular Lymp...
Diffuse Large B...
Primary Central...
NX-2127
18 Years - Nurix Therapeutics, Inc.
Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)NCT01497496
Chronic Lymphoc...
Small Lymphocyt...
High Dose Methy...
Ofatumumab
Lenalidomide
18 Years - H. Lee Moffitt Cancer Center and Research Institute
Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic DiseasesNCT02145039
Acute Leukemias
Burkitt's Lymph...
Chronic Myeloge...
Fludarabine
Cyclophosphamid...
Total Body Irra...
Haploidentical ...
- 74 YearsMasonic Cancer Center, University of Minnesota
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: